The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

被引：18

作者：

Wei, Qing ^{[1
,2
,3
]}

Li, Peijing ^{[2
,4
]}

Yang, Teng ^{[2
,5
]}

Zhu, Jiayu ^{[6
]}

Sun, Lu ^{[2
,7
]}

Zhang, Ziwen ^{[1
,2
]}

Wang, Lu ^{[8
]}

Tian, Xuefei ^{[2
,9
,10
]}

Chen, Jiahui ^{[2
,3
,11
]}

Hu, Can ^{[2
,3
,11
]}

Xue, Junli ^{[12
]}

Ma, Letao ^{[2
,5
]}

Shimura, Takaya ^{[13
]}

Fang, Jianmin ^{[14
]}

Ying, Jieer ^{[1
,2
,3
]}

Guo, Peng ^{[2
,3
]}

Cheng, Xiangdong ^{[2
,3
,11
]}

机构：

[1] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[2] Chinese Acad Sci, Hangzhou Inst Med HIM, Hangzhou, Peoples R China

[3] Upper Gastrointestinal Canc Zhejiang Prov, Key Lab Prevent Diag & Therapy, Hangzhou, Peoples R China

[4] Zhejiang Canc Hosp, Dept Radiat Oncol, Key Lab Head & Neck Canc Translat Res Zhejiang Pro, Hangzhou, Zhejiang, Peoples R China

[5] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou, Peoples R China

[6] Zhejiang Chinese Med Univ, Hangzhou, Peoples R China

[7] Zhejiang Canc Hosp, Dept Gynecol Oncol, Hangzhou, Peoples R China

[8] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China

[9] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China

[10] Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Coll Mol Med, Hangzhou, Peoples R China

[11] Zhejiang Canc Hosp, Dept Gastr Surg, Hangzhou, Peoples R China

[12] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China

[13] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Japan

[14] Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2024年 / 17卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Antibody-drug conjugate; Solid tumor; Combination therapy; Immunotherapy; Targeted therapy; TRASTUZUMAB EMTANSINE T-DM1; METASTATIC BREAST-CANCER; PLUS PEMBROLIZUMAB PEMBRO; DNA-DAMAGE RESPONSE; DERUXTECAN T-DXD; MIRVETUXIMAB SORAVTANSINE; PATIENTS PTS; SACITUZUMAB GOVITECAN; PLATINUM CHEMOTHERAPY; INELIGIBLE PATIENTS;

D O I：

10.1186/s13045-023-01509-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless, combination therapy does not always guarantee a synergistic or additive effect and may entail overlapping toxicity risks. Therefore, understanding the current status and underlying mechanisms of ADC combination therapy is urgently required. This comprehensive review analyzes existing evidence concerning the additive or synergistic effect of ADCs with other classes of oncology medicines. Here, we discuss the biological mechanisms of different ADC combination therapy strategies, provide prominent examples, and assess their benefits and challenges. Finally, we discuss future opportunities for ADC combination therapy in clinical practice.

引用

页数：32

共 50 条

[41] RETHINKING ANTIBODY-DRUG CONJUGATES
Jarvis, Lisa M.
CHEMICAL & ENGINEERING NEWS, 2012, 90 (25) : 12 - +
[42] Introduction to Antibody-Drug Conjugates
Pettinato, Mark C.
ANTIBODIES, 2021, 10 (04)
[43] Antibody-drug conjugates for cancer
Chau, Cindy H.
Steeg, Patricia S.
Figg, William D.
LANCET, 2019, 394 (10200): : 793 - 804
[44] Resistance to Antibody-Drug Conjugates
Garcia-Alonso, Sara
Ocana, Alberto
Pandiella, Atanasio
CANCER RESEARCH, 2018, 78 (09) : 2159 - 2165
[45] Antibody-Drug Conjugates (ADCs)
Laird, Trevor
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2014, 18 (09) : 1073 - 1073
[46] Payloads for Antibody-Drug Conjugates
Goundry, William R. F.
Parker, Jeremy S.
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2022, 26 (08) : 2121 - 2123
[47] Optimizing the safety of antibody-drug conjugates for patients with solid tumours
Tarantino, Paolo
Ricciuti, Biagio
Pradhan, Shan M.
Tolaney, Sara M.
NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (08) : 558 - 576
[48] The target atlas for antibody-drug conjugates across solid cancers
Fang, Jiacheng
Guo, Lei
Zhang, Yanhao
Guo, Qing
Wang, Ming
Wang, Xiaoxiao
CANCER GENE THERAPY, 2024, 31 (02) : 273 - 284
[49] The target atlas for antibody-drug conjugates across solid cancers
Jiacheng Fang
Lei Guo
Yanhao Zhang
Qing Guo
Ming Wang
Xiaoxiao Wang
Cancer Gene Therapy, 2024, 31 : 273 - 284
[50] Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
Dugal-Tessier, Julien
Thirumalairajan, Srinath
Jain, Nareshkumar
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 17

← 1 2 3 4 5 →